

Table S1. Characteristics of patients with hepatitis B virus (HBV) or hepatitis C virus (HCV) reactivation during secukinumab therapy

	HBV								HCV
	Pat #1 Chronic HBV infection	Pat #2 Chronic HBV infection	Pat #3 Chronic HBV infection	Pat #4 Chronic HBV infection	Pat #5 Chronic HBV infection	Pat #6 Chronic HBV infection	Pat #7 Occult HBV infection	Pat #8 Chronic HCV infection	
Viral hepatitis status	62/M	55/M	38/M	36/M	59/M	44/M	38/M	65/M	
Age, years/sex	6	5	24	11	15	13	12	15	
Duration of psoriasis, years	10	50	26	5	N/A	N/A	N/A	1	
Duration of hepatitis, years	34	28	133	40	12	58	71	22	
ALT level at baseline, IU/l	48	41	61	37	19	70	72	123	
ALT level at reactivation, IU/l	Undetectable	20	4310	515	31	180	20	15762	
Viral load at baseline, IU/ml	22	220	68800	8630	833	2277	220	706169	
Viral load at reactivation, IU/ml	N/N	N/Y	Y/N	N/N	N/N	N/Y	N/N	NA	
HBeAg/anti-HBe at baseline	ADA, UST, ETN	UST	ADA, UST	None	None	ADA, UST, ETN	UST, ETN	None	
Biological therapy prior to secukinumab treatment									
Secukinumab dose (mg)	300	300	300	150	300	300	300	300	
Patients with concomitant use of immunosuppressants	None	None	None	None	None	None	None	None	
Time to reactivation, months	1	1	9	3	1	6	3	3	
Treatment	Follow-up by a hepatologist without antiviral drugs	Follow-up by a hepatologist without antiviral drugs	Follow-up by a hepatologist without antiviral drugs	Entecavir 500 mg daily with hepatology follow-up	Telbivudine, 600 mg daily with hepatology follow-up	Telbivudine, 600 mg daily with hepatology follow-up	Follow-up by a hepatologist without antiviral drugs	Follow-up by a hepatologist without antiviral drugs	
Outcome	Remained stable, low-titre viral load, without HBV hepatitis	Remained stable, low-titre viral load, without HBV hepatitis	Asymptomatic, without HBV hepatitis	Viral load decreased, without HBV hepatitis	Viral load decreased, without HBV hepatitis	Viral load decreased, without HBV hepatitis	Remained stable, low-titre viral load, without HBV hepatitis	Fluctuating titre viral load, with hepatitis	
Follow-up duration, months	15	7	9	6	11	14	16	12	

ADA: adalimumab; ETN: etanercept; NA: not applicable; UST: ustekinumab.